Perspective Therapeutics (CATX) vs Quantum-Si (QSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Quantum-Si (QSI) has outperformed Perspective Therapeutics (CATX) over the past year, losing 12.1% versus a loss of 31.1%. Over five years, CATX leads with a -57.1% price change compared with -82.2% for QSI. Quantum-Si is the larger company by market cap ($334.9 million vs $303.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | QSI |
|---|---|---|
| Share price | $2.66 | $1.53 |
| Market cap | $303.64M | $334.89M |
| 1-day change | -1.85% | +25.41% |
| YTD return | -3.27% | +39.09% |
| 1-year return | -31.09% | -12.07% |
| 5-year return | -57.10% | -82.21% |
| EPS (TTM) | $-1.33 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $3.10 |
| 52-week low | $1.96 | $0.69 |
| Distance from 52-week high | -56.82% | -50.65% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +362.03% | +49.02% |
| Average volume | 1.65M | 4.17M |
| Shares outstanding | 114.15M | 198.95M |
| Employees | 163 | 145 |
| Sector | Healthcare | Industrials |
| Industry | Medical Devices | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QSI has outperformed CATX by 19.0 percentage points over the past year.
- The two companies sit in different sectors: Perspective Therapeutics in Healthcare and Quantum-Si in Industrials.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Healthcare · Medical Devices · 163 employees
About Quantum-Si
QSI stock →Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS.
Industrials · Industrial Machinery/Components · 145 employees
CATX vs QSI FAQ
Which is bigger, Perspective Therapeutics or Quantum-Si?
Quantum-Si (QSI) is larger, with a market capitalization of $334.89M compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or QSI?
QSI returned -12.07% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Quantum-Si in the same industry?
No. Perspective Therapeutics is in the Healthcare sector, while Quantum-Si is in Industrials.